Načítá se...
Treatment of NRAS-mutated advanced or metastatic melanoma: rationale, current trials and evidence to date
The disease course of BRAF (v-raf murine sarcoma viral oncogene homolog B1)-mutant melanoma has been drastically improved by the arrival of targeted therapies. NRAS (neuroblastoma RAS viral oncogene homolog)-mutated melanoma represents 15–25% of all metastatic melanoma patients. It currently does no...
Uloženo v:
| Vydáno v: | Ther Adv Med Oncol |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
SAGE Publications
2017
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5502949/ https://ncbi.nlm.nih.gov/pubmed/28717400 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758834017708160 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|